COMP <GO>
CLRB vs TVRD // GROSS PROFIT MARGIN
Cellectar Biosciences Inc. (NASDAQ) VS. Tvardi Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CLRB 2
— TVRD 0
■ METRIC PARITY
LAST: $1.22 (-1.61%) • MKT CAP: $11.5M
gross-margins
—
LAST: $0.86 (-2.73%) • MKT CAP: $11.5M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLRB VS. TVRD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLRB | TVRD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.1 | 27.2 | +2.92 | CLRB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.5M | $11.5M | $20.1K | CLRB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLRB REV | TVRD REV | CLRB GROSS % | TVRD GROSS % | CLRB FCF | TVRD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$23.1M | -$23.5M |
| FY 2024 | $0 | $7.1M | — | — | -$47.7M | -$19.4M |
| FY 2023 | $0 | $21.0M | — | — | -$32.4M | -$92.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLRB // BETA —
TVRD // BETA —